dc.contributor.author | Baral, Ranu | |
dc.contributor.author | White, Maddie | |
dc.contributor.author | Vassiliou, Vassilios S. | |
dc.date.accessioned | 2020-05-13T16:52:58Z | |
dc.date.available | 2020-05-13T16:52:58Z | |
dc.date.issued | 2020-05-08 | |
dc.identifier.uri | https://doi.org/10.1101/2020.05.03.20089375 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1465 | |
dc.description.abstract | Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS) notably Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB) have been scrutinised in hypertensive patients hospitalised with coronavirus disease 2019 (COVID-19) following some initial data they might adversely affect prognosis. With an increasing number of COVID-19 cases worldwide and the likelihood of a second wave of infection it is imperative to better understand the impact RAAS inhibitor use in antihypertensive covid positive hospitalised patients. A systematic review and meta-analysis of ACEi or ARB in patients admitted with COVID-19 was conducted. PubMed and Embase were searched and six studies were included in the meta-analysis. Pooled analysis demonstrated that 18.3% of the patients admitted with COVID-19 were prescribed ACEi/ARBs (0.183, CI 0.129 to 0.238, p<0.001). The use of RAAS inhibitors did not show any association with critical events (Pooled OR 0.833 CI 0.605 to 1.148, p=0.264) or death (Pooled OR 0.650, CI 0.356 to 1.187, p=0.161). In conclusion, our meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and hospitalised with COVID-19, found no evidence to associate ACEi/ARB with death or adverse events. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Hospitalization | en_US |
dc.subject | Meta-Analysis | en_US |
dc.subject | Systematic Review | en_US |
dc.subject | Renin-Angiotensin System | en_US |
dc.title | Impact of hospitalised patients with COVID-19 taking Renin-Angiotensin-Aldosterone System inhibitors: a systematic review and meta-analysis | en_US |
eihealth.country | Global (WHO/OMS) | en_US |
eihealth.category | Clinical characterization and management | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | medRxiv | en_US |